论文部分内容阅读
目的:观察分析血栓通联合依达拉奉治疗急性进展性脑梗死的效果,提高临床疗效、降低致残率和死亡率等。方法:选取90例急性进展性脑梗死患者且于同期将其分为联合用药治疗组和常规治疗组(每组45例),然后对其治疗效果和患者神经功能、日常生活能力情况进行观察,对相关数据进行统计分析。结果:联合用药治疗组总有效率为86.7%,且在改善神经功能、日常生活能力方面优于常规治疗组(P<0.05)。结论:血栓通联合依达拉奉治疗急性进展性脑梗死疗效显著,是一种行之有效的治疗方法。
Objective: To observe the effect of Xuesaitong combined with edaravone in the treatment of acute progressive cerebral infarction, to improve the clinical curative effect, reduce the morbidity and mortality. Methods: Ninety patients with acute progressive cerebral infarction were selected and divided into two groups: the combination therapy group and the conventional therapy group (45 cases in each group) during the same period. Then their therapeutic effects, neurological function and daily living ability were observed, The relevant data for statistical analysis. Results: The total effective rate of combination therapy group was 86.7%, which was superior to routine treatment group in improving neurological function and daily living ability (P <0.05). Conclusion: Xuesaantong combined with edaravone has a significant therapeutic effect on acute progressive cerebral infarction, which is an effective treatment.